High-dose Dual Therapy and Minocycline-cotaining Quadruple Therapy for Helicobacter Pylori Infection

Shanghai Jiao Tong University School of Medicine

Status and phase

Enrolling

Phase 4

Conditions

Helicobacter Pylori Infection

Treatments

Drug: Amoxicillin

Drug: Vonoprazan

Drug: Bismuth Potassium Citrate

Drug: Minocycline,Metronidazole

Study type

Interventional

Funder types

Other

Identifiers

NCT06561698

rjhy20240814

Details and patient eligibility

About

This study is a multicentra, prospective study. The enrolled patients are HP positive. They are diagnosed as HP positive by rapid urease test and/or 13C urea breath test. According to the declaration of Helsinki, 200 patients will be included in this study. After obtaining the written informed consent of the patients, HP culture and drug sensitivity test will be conducted on all the selected patients with the success rate, adverse reactions, compliance, antibiotic resistance of HP and its impact on HP eradication.

Enrollment

200 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Ability and willingness to participate in the study and to sign and give informed consent
Confirmed H. pylori infection

Exclusion criteria

Pregnant and lactating women;
History of gastrointestinal malignancies;
History of previous subtotal gastrectomy;
Serious dysfunction of heart, liver, kidney, lung and other important organs and congenital diseases; Such as grade IV cardiac insufficiency, liver failure, uremia, respiratory failure, hemophilia, Wilson disease, etc;
History of hematological diseases
People who are allergic to drugs;
The guardian or patient refused to join the group;
Alcohol and / or drug abuse (addiction or dependence) or poor compliance judged by doctors;
No legal capacity or poor self-knowledge
administration of antibiotics, bismuth, antisecretory drugs, or Chinese herb medicine in the preceding 8 weeks